Argus analyst David Toung raised the firm’s price target on HCA Healthcare to $285 from $260 and keeps a Buy rating on the shares. The company is seeing higher non-COVID patient admissions and surgical volumes, though it is also facing earnings headwinds as its hospitals cope with higher costs for labor and supplies, the analyst tells investors in a research note. While the firm is cutting its FY23 EPS view by 80c to $17.40, it also views HCA Healthcare shares as favorably valued at 14.7-times its 2023 EPS estimate, which is below the peer average of 17.3-times.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HCA:
- HCA Healthcare exec Berres sells 4,000 common shares
- HCA Healthcare price target raised to $300 from $230 at Raymond James
- HCA Healthcare price target raised to $285 from $240 at Loop Capital
- HCA Healthcare price target raised to $283 from $239 at RBC Capital
- HCA Healthcare price target raised to $290 from $270 at Truist
